The World Health Organization unveiled a six-month plan to stamp out the current Bundibugyo Ebola virus outbreak, including a scale-up of point-of-care molecular diagnostics supplied through KH Medical’s RadiOne PCR system. WHO said the total investment needed for the plan is about $518 million, with emphasis on speeding detection and strengthening reference labs. Roche also disclosed development of a research-use-only PCR test to detect Bundibugyo Ebola, citing Lancet commentary warning that lack of fit-for-purpose testing is hampering assessment of outbreak scale and transmissibility. WHO and partners are combining diagnostic production, tech transfer, and sequencing-based surveillance capacity to improve outbreak visibility. For biotech diagnostics, the sequence of announcements points to practical demand for deployable molecular tools that can be produced and transferred quickly—especially for rare viral strains where testing coverage can become the limiting factor for public-health response.